Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.

The pharmacogenomics journal - 1 Aug 2016

Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Fujimoto Y, Ueno M, Lenz H-J

Abstract excerpt

The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil (5-Fu). In this study, 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyltransferases
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to California

Share to Chemotherapy, Adjuvant

Share to Colectomy

Share to Colonic Neoplasms

Share to Fluorouracil

Share to Neoplasm Recurrence, Local

Source

Open in PubMed Open full text

Identifiers

PMID: 26370619
DOI: 10.1038/tpj.2015.64
PMCID: PMC4792794

Genes

FAT4
LATS1
LATS2
MST1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.PMID 26370619Read ↗

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.Semantic proximity Read ↗

Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon CancersSemantic proximity Read ↗

Genetic variants in Hippo signalling pathway-related genes affect the risk of colorectal cancer.Semantic proximity Read ↗

Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.Semantic proximity Read ↗

A novel epigenetic signature to predict recurrence-free survival in patients with colon cancerSemantic proximity Read ↗

LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.Semantic proximity Read ↗

PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancerSemantic proximity Read ↗

Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.Semantic proximity Read ↗

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based studySemantic proximity Read ↗

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.Semantic proximity Read ↗

GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes.Semantic proximity Read ↗

Common cancer stem cell gene variants predict colon cancer recurrence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.